Anticorps Recombinant de lapin anti-KIR3DL1/CD158E

KIR3DL1/CD158E Recombinant Antibody for FC

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

FC

Conjugaison

Non conjugué

CloneNo.

243022H8

N° de cat : 98389-1-RR

Synonymes

KIR3DL1, CD158 antigen-like family member E, CD158E, CD158E1, HLA-BW4-specific inhibitory NK cell receptor



Applications testées

Résultats positifs en cytométrieCMSP humaines,

Dilution recommandée

ApplicationDilution
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

98389-1-RR cible KIR3DL1/CD158E dans les applications de FC et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène Protéine recombinante
Nom complet killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1
Masse moléculaire calculée49 kDa
Numéro d’acquisition GenBankNM_013289.4
Symbole du gène KIR3DL1
Identification du gène (NCBI) 3811
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS with 0.09% sodium azide
Conditions de stockageStore at 2 - 8°C. Stable for one year after shipment.

Informations générales

Killer cell immunoglobulin-like receptors (KIRs) are transmembrane glycoproteins expressed by natural killer cells and subsets of T cells. The KIR proteins are classified by the number of extracellular immunoglobulin domains (2D or 3D) and by whether they have a long (L) or short (S) cytoplasmic domain. KIR3DL1 is a receptor on natural killer (NK) cells for HLA Bw4 allele. It inhibits the activity of NK cells thus preventing cell lysis. KIR3DL1 and KIR3DS1 are highly homologous.

Protocole

Product Specific Protocols
FC protocol for KIR3DL1/CD158E antibody 98389-1-RRDownload protocol
Standard Protocols
Click here to view our Standard Protocols
{{ptg:RelatedPrimaryAntibodies}}